Monday, September 28, 2015
Shares in Novo Nordisk rose as much as 5 percent on Monday after the U.S. Food and Drug Administration (FDA) late on Friday approved the Danish drugmaker's diabetes drug Tresiba, two years after rejecting the long-acting form of insulin.
The agency also approved the company's Ryzodeg, an injection that combines Tresiba and a fast-acting form of insulin.
reuters.com
